Ad hoc analysis of behavior and time as co-variates of the Thai phase III efficacy trial: RV 144

BACKGROUND: The Thai phase III HIV vaccine trial's modest efficacy (VE 31.2% 95% CI 1.1, 51.2) represents the first demonstration that a vaccine can protect against HIV acquisition. Baseline variables of age, gender, marital status, and risk did not modify vaccine efficacy (VE). Here we explore...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Robb, Merlin L., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Kunasol, Prayura, Khamboonruang, Chirasak, Thongcharoen, Prasert, Morgan, Patricia, Benenson, Michael, Paris, Robert M., Chiu, Joseph, Adams, Elizabeth, Francis, Donald, Gurunathan, Sanjay, Tartaglia, Jim, Gilbert, Peter, Stablein, Don, Michael, Nelson L., Kim, Jerome H.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3530398/
https://ncbi.nlm.nih.gov/pubmed/22652344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(12)70088-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items